检索结果-南通市图书馆

Asian Journal of Andrology 2012年第3期14卷 355-360,I0004页

作者： H Ballentine Carter Department of Urology Johns Hopkins University School of Medicine Johns Hopkins Hospital Baltimore MD 21287-2101 USA

Prostate-specific antigen （psa） testing for the early diagnosis of prostate cancer has led to a decrease in cancer mortality. However, the high prevalence of low-grade prostate cancer and its long natural history, competing causes of death in older men and treatment patterns of prostate cancer, have led to dramatic overtreatment of the disease. Improved markers of prostate cancer lethality are needed to reduce the overtreatment of prostate cancer that leads to a reduced quality of life without extending life for a high proportion of men. The psa level prior to treatment is routinely used in multivariable models to predict prostate cancer aggressiveness. psa isoforms and psa kinetics have been associated with more aggressive phenotypes, but are not routinely employed as part of prediction tools prior to treatment. psa kinetics is a valuable marker of lethality post treatment and routinely used in determininE the need for salva=e theraov.

关键词： benign psa human kallikrein 2 precursor form of psa prostate specific antigen psa kinetics unbound or free psa

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

The Use of psa Doubling Time to Predict Prognosis and the Use of psa Response to Assess the Success for Prostate Cancer Patients Undergoing Docetaxel Chemotherapy

引用

Journal of Cancer Therapy 2016年第8期7卷 593-599页

作者： Sarp K. Keskin Asif Yildirim Cengiz Canakci Ismail Ulus Ramazan Gokhan Atis Turhan Caskurlu Department of Urology The University of Texas MD Anderson Cancer Center Houston USA Department of Urology The University of Istanbul Medeniyet Goztepe Training and Research Hospital Istanbul Turkey

In the targeted therapy era, it is critical to know the certain points to start or discontinue chemotherapy for patients with castration resistant metastatic prostate cancer. The prognostic factors to determine this response are still not clear yet. We tried to find out if the psa doubling time helps us to predict the patients who will benefit from docetaxel chemotherapy most, and also to question the value of the psa response to chemotherapy. Retrospectively, 70 patients who had hormone refractory metastatic prostate cancer that were given at least 4 cycles of docetaxel chemotherapy between 2002 and 2015 were evaluated. After the onset of docetaxel, psa response to therapy and overall survival rates were analyzed to figure out if these parameters were related to psa doubling time. The only statistically significant prognostic parameter affecting overall survival was the best psa response rate to docetaxel chemotherapy being over or under 50%. The most significant parameter that affects the psa doubling time was the clinical stage at the time of diagnosis. psa doubling time is not a useful predictive tool for predicting response to docetaxel. By means of overall survival, the clinical stage at the time of diagnosis was the best predictive tool for our cohort. The best psa response rate to docetaxel chemotherapy was found to be a valuable parameter. The study being retrospective and the low number of patients included in this cohort can be the main weaknesses of this study. Further studies to determine which other factors can be useful are needed.

关键词： Castration Resistant Prostate Cancer Docetaxel psa Doubling Time psa kinetics Chemotherapy

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：